Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib with Chemotherapy in Pediatric Relapsed/Refractory ALL
NCT02303821Phase 1Completed
- Sponsor
- Amgen
- Start
- Feb 2015
- Primary completion
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 33
01
Overview
Phase 1, open-label trial of carfilzomib in acute lymphoblastic leukemia (ALL) (4 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) up to 35 days and 1 more. Started Feb 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02303821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303821.